Since joining Samsung Biologics in 2025, Jina Kang has completed ADC method development projects optimized for linker–payload analysis and DAR assessments. She holds a master’s degree in biology from Dongguk University and has over a decade of experience in MS-based characterization within the biologics industry. Before joining Samsung Biologics, she worked at Hanmi Pharmaceutical, where she supported method development and the commercial launch of PEGylated fusion proteins.